Specialized Solid Form Screening Techniques
暂无分享,去创建一个
[1] Patrick Marroum,et al. Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus , 2012 .
[2] J. Ketolainen,et al. Computational approach for fast screening of small molecular candidates to inhibit crystallization in amorphous drugs. , 2012, Molecular pharmaceutics.
[3] H. Ohno,et al. Ionic liquid/water mixtures: from hostility to conciliation. , 2012, Chemical communications.
[4] Claire S. Adjiman,et al. Towards crystal structure prediction of complex organic compounds – a report on the fifth blind test , 2011, Acta crystallographica. Section B, Structural science.
[5] L. Casettari,et al. Poloxamer Thermogel Systems as Medium for Crystallization , 2011, Pharmaceutical Research.
[6] Sarah L Price,et al. Computational prediction of salt and cocrystal structures--does a proton position matter? , 2011, International journal of pharmaceutics.
[7] S. R. Bysouth,et al. Cocrystallization via planetary milling: enhancing throughput of solid-state screening methods. , 2011, International journal of pharmaceutics.
[8] Jia Liu,et al. Medium-throughput hydrate screening using the Crystal 16™ , 2011, Pharmaceutical development and technology.
[9] Beatrice Perissutti,et al. Enhanced Oral Bioavailability of Vinpocetine Through Mechanochemical Salt Formation: Physico-Chemical Characterization and In Vivo Studies , 2011, Pharmaceutical Research.
[10] D. Ende,et al. Chemical engineering in the pharmaceutical industry : R&D to manufacturing , 2010 .
[11] S. Byrn,et al. A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. , 2010, Journal of pharmaceutical sciences.
[12] Keith R Horspool,et al. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. , 2010, Journal of pharmaceutical sciences.
[13] J. Rantanen,et al. Towards effective solid form screening. , 2010, Journal of pharmaceutical sciences.
[14] Woo-Sik Kim,et al. Application of Ionic Liquid to Polymorphic Design of Pharmaceutical Ingredients , 2010 .
[15] Henrique A. Matos,et al. Screening for pharmaceutical cocrystals using the supercritical fluid enhanced atomization process , 2010 .
[16] J. McCabe. Application of design of experiment (DOE) to polymorph screening and subsequent data analysis , 2010 .
[17] Jan Van Humbeeck,et al. Influence of Preparation Methods on Solid State Supersaturation of Amorphous Solid Dispersions: A Case Study with Itraconazole and Eudragit E100 , 2010, Pharmaceutical Research.
[18] D. Macfarlane,et al. Crystalline vs. Ionic Liquid Salt Forms of Active Pharmaceutical Ingredients: A Position Paper , 2010, Pharmaceutical Research.
[19] Bing-Shiou Yang,et al. A Practical Solid Form Screen Approach To Identify a Pharmaceutical Glutaric Acid Cocrystal for Development , 2009 .
[20] Luis Padrela,et al. Formation of indomethacin-saccharin cocrystals using supercritical fluid technology. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] P. Karamertzanis,et al. Salt or Cocrystal? A New Series of Crystal Structures Formed from Simple Pyridines and Carboxylic Acids , 2009 .
[22] I. Miroshnyk,et al. Pharmaceutical co-crystals–an opportunity for drug product enhancement , 2009, Expert opinion on drug delivery.
[23] Richard W. Duerst,et al. Cocrystals of Caffeine and Hydroxybenzoic Acids Composed of Multiple Supramolecular Heterosynthons: Screening via Solution-Mediated Phase Transformation and Structural Characterization , 2009 .
[24] S. Childs,et al. The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome , 2009 .
[25] D. Macfarlane,et al. Exploring an Anti-Crystal Engineering Approach to the Preparation of Pharmaceutically Active Ionic Liquids , 2009 .
[26] David R. Weyna,et al. Synthesis and Structural Characterization of Cocrystals and Pharmaceutical Cocrystals: Mechanochemistry vs Slow Evaporation from Solution , 2009 .
[27] P. Karamertzanis,et al. Can the Formation of Pharmaceutical Cocrystals Be Computationally Predicted? I. Comparison of Lattice Energies , 2009 .
[28] Jukka Rantanen,et al. Solid form screening--a review. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[29] Yong Cui,et al. Evaluation of hydrate-screening methods. , 2008, Journal of pharmaceutical sciences.
[30] N. Rodríguez-Hornedo,et al. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine , 2008 .
[31] K. Terada,et al. Cocrystal Screening of Stanolone and Mestanolone Using Slurry Crystallization , 2008 .
[32] Wen-ting Cheng,et al. Famotidine polymorphic transformation in the grinding process significantly depends on environmental humidity or water content. , 2008, International journal of pharmaceutics.
[33] Enxian Lu,et al. Stable-form screening: overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine. , 2008, Journal of pharmaceutical sciences.
[34] Raj Suryanarayanan,et al. A rapid thermal method for cocrystal screening , 2008 .
[35] C. C. Seaton,et al. Applying Hot-Stage Microscopy to Co-Crystal Screening: A Study of Nicotinamide with Seven Active Pharmaceutical Ingredients , 2008 .
[36] M. Sherry Ku,et al. Use of the Biopharmaceutical Classification System in Early Drug Development , 2008, The AAPS Journal.
[37] Gary Eichenbaum,et al. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing. , 2008, International journal of pharmaceutics.
[38] Shayne C. Gad,et al. Preclinical Development Handbook , 2008 .
[39] Lokesh Kumar,et al. An overview of automated systems relevant in pharmaceutical salt screening. , 2007, Drug discovery today.
[40] A. Matzger,et al. New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation. , 2007, Journal of pharmaceutical sciences.
[41] G. P. Stahly. Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Cocrystals , 2007 .
[42] David R. Weyna,et al. Hierarchy of supramolecular synthons: persistent hydroxyl...pyridine hydrogen bonds in cocrystals that contain a cyano acceptor. , 2007, Molecular pharmaceutics.
[43] T. Friščić,et al. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. , 2007, Molecular pharmaceutics.
[44] Ron J Roberts,et al. Structure, solubility, screening, and synthesis of molecular salts. , 2007, Journal of pharmaceutical sciences.
[45] Geoff G. Z. Zhang,et al. Efficient co-crystal screening using solution-mediated phase transformation. , 2007, Journal of pharmaceutical sciences.
[46] W. Jones,et al. Screening for crystalline salts via mechanochemistry. , 2006, Chemical communications.
[47] William Jones,et al. Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement , 2006 .
[48] Aeri Park,et al. Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.
[49] P. Dyson,et al. 1H, 19F-HOESY and PGSE diffusion studies on ionic liquids: The effect of co-solvent on structure , 2006 .
[50] Sarah J. Nehm,et al. Reaction crystallization of pharmaceutical molecular complexes. , 2006, Molecular pharmaceutics.
[51] Sarah J. Nehm,et al. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation , 2006 .
[52] Alfred Y Lee,et al. Factors Affecting the Polymorphic Outcome of Glycine Crystals Constrained on Patterned Substrates , 2006 .
[53] Alfred Y Lee,et al. Influence of Impurities on the Solution-Mediated Phase Transformation of an Active Pharmaceutical Ingredient , 2005 .
[54] A. Matzger,et al. Crystalline polymorph selection and discovery with polymer heteronuclei. , 2005, Journal of the American Chemical Society.
[55] David J W Grant,et al. Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.
[56] A. Goho. Tricky business: The crystal form of a drug can be the secret to its success , 2004 .
[57] Åke C. Rasmuson,et al. Influence of Additives on Nucleation of Vanillin: Experiments and Introductory Molecular Simulations , 2004 .
[58] William Jones,et al. Solvent-drop grinding: green polymorph control of cocrystallisation. , 2004, Chemical communications.
[59] W. Curatolo,et al. Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.
[60] Geoff G. Z. Zhang,et al. Phase transformation considerations during process development and manufacture of solid oral dosage forms. , 2004, Advanced drug delivery reviews.
[61] Michael J Cima,et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.
[62] J. Bauer,et al. Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.
[63] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[64] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[65] D. Grant,et al. Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. , 2001, Journal of pharmaceutical sciences.
[66] B. Shekunov,et al. Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS). , 2001, Journal of pharmaceutical sciences.
[67] W. Beckmann,et al. Crystallisation of the Stable Polymorph of Hydroxytriendione: Seeding Process and Effects of Purity , 2001 .
[68] Michael B. Hursthouse,et al. Over one hundred solvates of sulfathiazole , 2001 .
[69] C. A. Mitchell,et al. Crystallization and Polymorphism of Conformationally Flexible Molecules: Problems, Patterns, and Strategies , 2000 .
[70] C. Rustichelli,et al. Solid-state study of polymorphic drugs: carbamazepine. , 2000, Journal of pharmaceutical and biomedical analysis.
[71] S. Chemburkar,et al. Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development , 2000 .
[72] H. Brittain. Polymorphism in Pharmaceutical Solids , 1999 .
[73] G. Desiraju,et al. Pseudopolymorphism: occurrences of hydrogen bonding organic solvents in molecular crystals , 1999 .
[74] Y. Marcus. The properties of solvents , 1998 .
[75] Suryanarayanan,et al. Applications of pressure differential scanning calorimetry in the study of pharmaceutical hydrates. I. Carbamazepine dihydrate. , 1997, International journal of pharmaceutics.
[76] A. Dzyabchenko,et al. X-ray characterization of the triclinic polymorph of carbamazepine. , 1997, Journal of pharmaceutical sciences.
[77] P. York,et al. Characterization of dihydrates prepared from carbamazepine polymorphs. , 1996, Journal of pharmaceutical sciences.
[78] D. Grant,et al. Research paperInfluence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. Theophylline , 1996 .
[79] M. C. Etter. Encoding and decoding hydrogen-bond patterns of organic compounds , 1990 .
[80] F. Lefaucheux,et al. Crystal growth in gels: Principle and applications , 1988 .
[81] F. Krahn,et al. Relations between several polymorphic forms and the dihydrate of carbamazepine. , 1987, Pharmaceutica acta Helvetiae.
[82] S. Suib. Crystal growth in gels , 1985 .
[83] Donald C. Monkhouse,et al. Review ArticlePharmaceutical Salts , 1977 .
[84] W. Powrie,et al. Gas hydrates in aqueous-organic systems. 3. Hydrate formation in polyacrylamide gel. , 1966, Cryobiology.